ReviewFrontiers in medicine2015
Chronic Kidney Disease and Fibrosis: The Role of Uremic Retention Solutes.
Review in Frontiers in medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 79 citations in OpenAlex.
- Lacticaseibacillus rhamnosus attenuates uremic toxins in patients with nondialysis chronic kidney disease through the anti-inflammatory molecules.Scientific reports · 2025Trial
- Chronic Kidney Disease Severity Is Associated With Selective Expansion of a Distinctive Intermediate Monocyte Subpopulation.Frontiers in immunology · 2018Trial
- Role of novel renal biomarkers in predicting the prognosis of patients with chronic kidney disease: a prospective cohort study.Turkish journal of medical sciences · 2026Article
- Metabolomics reveals alterations in gut-derived uremic toxins and tryptophan metabolism in feline chronic kidney disease.The veterinary quarterly · 2025Article
- Gut microbiota dysbiosis in hyperuricaemia promotes renal injury through the activation of NLRP3 inflammasome.Microbiome · 2024Article
- Causal relationship between gut microbiota and chronic renal failure: a two-sample Mendelian randomization study.Frontiers in microbiology · 2024Article
- The Gut-Peritoneum Axis in Peritoneal Dialysis and Peritoneal Fibrosis.Kidney medicine · 2023Review
- Canagliflozin protects the cardiovascular system through effects on the gut environment in non-diabetic nephrectomized rats.Clinical and experimental nephrology · 2023Article
- Aryl Hydrocarbon Receptor in Oxidative Stress as a Double Agent and Its Biological and Therapeutic Significance.International journal of molecular sciences · 2022Review
- Uremia-Induced Gut Barrier Defect in 5/6 Nephrectomized Mice Is Worsened byInternational journal of molecular sciences · 2022Article
- Mitochondrial Pathophysiology on Chronic Kidney Disease.International journal of molecular sciences · 2022Review
- Renoprotective Effects of Maslinic Acid on Experimental Renal Fibrosis in Unilateral Ureteral Obstruction Model via Targeting MyD88.Frontiers in pharmacology · 2021Article
- Effect of Kidney Transplantation on Accelerated Immunosenescence and Vascular Changes Induced by Chronic Kidney Disease.Frontiers in medicine · 2021Article
- Hepatitis B and C Infections in Patients With Prolonged Hemodialysis Secondary to Chronic Renal Failure.Cureus · 2020Article
- Hippuric Acid Promotes Renal Fibrosis by Disrupting Redox Homeostasis via Facilitation of NRF2-KEAP1-CUL3 Interactions in Chronic Kidney Disease.Antioxidants (Basel, Switzerland) · 2020Article
- Melatonin Suppresses Renal Cortical Fibrosis by Inhibiting Cytoskeleton Reorganization and Mitochondrial Dysfunction through Regulation of miR-4516.International journal of molecular sciences · 2020Article
- Article
- Female AhR Knockout Mice Develop a Minor Renal Insufficiency in an Adenine-Diet Model of Chronic Kidney Disease.International journal of molecular sciences · 2020Article
- Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.Kidney international · 2020Article
- The Aryl Hydrocarbon Receptor in Chronic Kidney Disease: Friend or Foe?Frontiers in cell and developmental biology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease (CKD) is a major global health concern, and the uremic state is highly associated with fibrogenesis in several organs and tissues. Fibrosis is characterized by excessive production and deposition of extracellular matrix proteins with a detrimental impact on organ function. Another key feature of CKD is the retention and subsequent accumulation of solutes that are normally cleared by the healthy kidney. Several of these uremic retention solutes, including indoxyl sulfate and p-cresyl sulfate, have been suggested to be CKD-specific triggers for the development and perpetuation of fibrosis. The purpose of this brief review is to gather and discuss the current body of evidence linking uremic retention solutes to the fibrotic response during CKD, with a special emphasis on the pathophysiological mechanisms in the kidney.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.